Clinical Trial Update: Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) [Phase 3]

View source ↗

Summary

A Phase 3 pediatric trial is evaluating oral ubrogepant for acute treatment of migraine in children and adolescents (6-17) and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Ubrelvy (ubrogepant)

Snippet

Sponsor: AbbVie | Conditions: Migraine | Phase 3 | Status: RECRUITING